A cholinergic locus has recently been identified consisting of a unique mammalian genomic arrangement containing the genes for choline acetyltransferase (ChAT) and a putative vesicular acetylcholine transporter (VAChT). Although transcripts for ChAT and VAChT protein have been localized in cholinergic neurons, little is known about the encoded VAChT protein. Here we describe production of highly specific rabbit polyclonal antibodies, generated using a VAChT C-terminus/glutathione-S-transferase fusion protein, and immunological characterization of the native VAChT protein. These antibodies specifically recognized full-length recombinant VAChT expressed in transfected HeLa cells by Western blotting, with the prominent immunoreactive band at 55 kDa. In rat brain homogenates, a single VAChT-immunoreactive band of -70 kDa was predominant in known areas of cholinergic innervation, including striatum, cortex, hippocampus, and amygdala. Light microscopic immunocytochemistry revealed reaction product in cholinergic cell groups but not in noncholinergic areas. More significantly, immunoreactivity was also concentrated in axonal fibers in many regions known to receive prominent cholinergic innervation, such as cerebral cortex, hippocampus, amygdala, striaturn, several thalamic nuclei, and brainstem regions. Electron microscopy using immunoperoxidase revealed that VAChT was localized in axon terminals, and using more precise immunogold techniques, to synaptic vesicles. In VAChT-positive perikarya, the immunogold particles were localized to the cytoplasmic face of the Golgi complex. These findings confirm that VAChT protein is expressed uniquely in cholinergic neurons, concentrated in synaptic vesicles, and at least for the C terminus, topologically oriented as predicted by models.
Key words: vesicular acetylcholine transporter; cholinergic; presynaptic; synaptic vesicles; antibodies; transporters Cholinergic neurotransmission in the CNS is dependent on three proteins that are believed to define cholinergic neurons uniquely: choline acetyltransferase (ChAT), the enzyme that synthesizes acetylcholine;
high-affinity choline transporter (HAChT), the sodium-dependent plasma membrane transporter that recycles choline formed from the breakdown of acetylcholine in the synaptic cleft by acetylcholinesterase; and vesicular acetylcholine transporter (VAChT), the proton-dependent transporter that packages acetylcholine synthesized in the cytoplasm into synaptic vesicles. To date, ChAT has been the most widely studied and has revealed the prominent role of cholinergic transmission in Alzheimer's disease and other nervous system disorders (Coyle et al., 1983) .
Recent cloning of the putative VAChT gene revealed that a single genetic locus encodes both ChAT and VAChT, providing a unique genetic mechanism for governing the cholinergic phenotype of neurons (Alfonso et al., 1993; Bejanin et al., 1994; Erickson et al., 1994; Roghani et al., 1994) . Hydropathy analysis of the VAChT-predicted amino acid sequence suggests a protein with 12 transmembrane domains, with the N and C termini in the cyto-plasm, and a large intravesicular loop between transmembrane domains I and II. Sequence homology places VAChT into a family of transporter proteins that includes two vesicular monoamine transporters (VMATs).
These vesicular transporters are believed to concentrate neurotransmitters in synaptic vesicles through exchange of protons for neurotransmitter; however, attempts to determine the kinetic parameters of acetylcholine transport have been unsuccessful because of low transport levels in heterologous expression systems (Erickson et al., 1994) . Additionally, the localization of the VAChT protein to synaptic vesicles remains unproven. In rats and humans, the coding sequence for VAChT is contained completely within the first intron of the ChAT gene. Moreover, mRNAs isolated from rat spinal cord have shown that some transcripts of VAChT and ChAT share a 5' untranslated cxon (Bejanin et al., 1994; Cervini et al., 1995) . This is similar to the arrangement observed in Caenwhabditis elegans (Alfonso et al., 1994) . In situ hybridization studies suggest that expression patterns of VAChT and ChAT mRNAs are coupled tightly in the CNS, possibly because of shared genetic regulatory elements (Schafer et al., 1994) . "H-vesamicol binding autoradiography in Alzheimer's disease tissue, however, suggests that this regulation may be uncoupled in disease states, because levels of VAChT binding are unchanged or increased despite the marked reductions in ChAT (Kish et al., 1990; Ruberg et al., 1990) . Further understanding of the regulation, subcellular targeting, and topology of the putative VAChT molecule demands new approaches for study at the protein level.
The purpose of the present study was to produce selective polyclonal antibodies to the VAChT and to characterize the native protein in brain. Rabbit polyclonal antifusion protein antibodies directed against the C terminus were developed, and specificity was established by immunoblotting. The antibodies were then used to identify VAChT protein in rat brain, establishing its expression uniquely in cholinergic neurons, and to confirm its localization in synaptic vesicles. Moreover, the cytoplasmic localization of the C terminus is consistent with models of VAChT protein topology.
MATERIALS AND METHODS
VAChT-pGEX-2T plasmid construction and expression. A fusion protein incorporating the putative C terminus (Ct; amino acids 478-530) of the rat VAChT (Roghani et al., 1994) was produced with the pGEX-2T bacterial expression system (Smith and Johnson, 1988) . The cDNA encoding the carboxyl terminus was subcloned using PCR (Perkin-Elmer/ Cetus, Norwalk, CT) to amplify the region between nucleotides 2290 and 2452 of the cloned rat VAChT. To facilitate successful subcloning and correct fragment orientation, primers were designed (5'-TTAATTG-GATCCTCGCGTICGGAGCGCGATGTG and 5'-TTAATTGAATTC-GCTAGCTGCGGGAGTAATAG'IT) with either of two restriction sites (BamHI or EcoRI), introduced into forward and reverse primers, respectively (marked by italics in above sequences). Full-length rat VAChT cDNA was used as template for PCR reactions. Amplified DNA segments were purified and subcloned between the BamHI and EcoRI sites of pGEX-2T. Recombinants were sequenced by the dideoxynuclcotide chain-termination method using Sequenase version 2.0 (United States Biochemical, Cleveland, OH) and 7-deaza-dGTP.
The encoded fusion protein contains a 27 kDa fragment of hclminthic glutathione-S-transferase (GST) fused at the C terminus with the rat VAChT C terminus. The fusion protein was expressed in Escherichia co/i [BL21 (DE3) strain] cells transformed with the pGEX-2T plasmids. Cells were grown to an OD,,, of 0.4 and were pelleted after 3-4 hr of induction by isopropylthiogalactoside. Pre-and postinduction culture samples were analyzed by SDS-PAGE to reveal intense de novo protein bands. The induced bacteria were lysed by incubation with lysozyme and repeated freezing and thawing. The soluble fusion protein was affinity-purified from the bacterial lysates against immobilized glutathione conjugated to epoxy-activated agarose (Sigma, St. Louis, MO) and eluted with excess free reduced glutathione. Purified fusion protein preparations were verified by SDS-PAGE analysis. Fusion proteins were also made containing the N terminus (amino acids l-33) and the intravesicular loop (amino acids 61-121); however, these proteins did not produce useful antibodies or were insoluble and thus are not discussed further. Antibody production. A New Zealand white rabbit was immunized for polyclonal antibody production with the Ct-fusion protein. The animal received a primary injection of 500 pg Ct-fusion protein emulsified in complete Freund's adjuvant and subsequent monthly boost injections of -200 pg of Ct-fusion protein emulsified in incomplete Freund's adjuvant. Bleeds were obtained at 3 and 4 weeks postboost, clotted overnight at 4"C, and clarified, and the sera were aliquotted and frozen at -80°C. Antibodies to GST were removed specifically by passage over columns of GST and GST/BL21(DE3) lysate conjugated to Affi-Gel 15 (BioRad, Richmond, CA). Antibodies to the C terminus were subsequently purified on Ct-fusion protein conjugated to Affi-Gel 15.
Cell transfections. Rat VAChT cDNA was transfected into HeLa cells using the vaccinia-T7 expression system (Fuerst et al., 1986; Blakely et al., 1991) . The parent vector pBluescript SKII (Stratagene, La Jolla, CA) was transfected in parallel as a negative control for transporter expression. Briefly, 10 cm dishes were seeded with HeLa cells (3 X 10h cell/plate; American Type Tissue Collection, Rockville, MD) 1 d before transfection. Media were removed, and virus (VTF7-3, 5 pfu/cell) was added to cells in OPTI-MEM (Life Technologies, Gaithersburg, MD) supplemented with 55 FM 2-mcrcaptoethanol for 30 min, followed by the addition of DNA (5 &dish) as a liposome suspension with a 2:l lipid to DNA ratio (v/v) (Life Technologies). Transfected cells were harvested 18 hr after transfection for immunoblots.
Immunoblot analysis. Western blots were performed as described previously (Ciliax et al., 1995 Figure 1 . Characterization and specificity of VAChT C-terminus antibodies by Western blotting. A, SDS-PAGE was performed on GST (GST, 500 ng), purified C-terminus fusion protein (GST-Ct, 10 ng), HeLa cells transfected with pBluescript vector only @BS, 10 yg), and HeLa cells transfected with VAChT cDNA (pBS-VAChT, 10 pg). The blots were probed with affinity-purified C-terminus antibodies (0.5 &ml) before (-) or after (+) preadsorption on 100 Fg of homologous fusion protein conjugated to Affi-Gel 15 and developed for 1 min as described in Materials and Methods. B, HeLa cells transfected with pBluescript (50 pg) or VAChT (50 pg) and brain homogenates (100 pg/ml), as indicated, and developed for 5 min. Abbreviations: OB, olfactory bulb; PFCX, prefrontal cortex; CX, cortex; STR, striatum; BF, basal forebrain; HIP, hippocampus; THAL, thalamus; AMYG, amygdala; MB, midbrain; CB, cerebellum; P/M, ponsimedulla. VAChT and ChAT immunoreactivity were evaluated on adjacent sections of rat brai n proccsscd for immunocytochemistry as described i n Materials and Methods. The relative density of immunopositive somata or puncta/fibers was subjectively rated as follows: (-) absent; (f) low; (+ f) moderate; (f + +) high; (f + + f) very high. In cortex, faintly l abel ed neurons were observed i n some but not all cases and thus are l abel ed as uncertain (?). In several cranial nerve motor nuclei, large puncta decorated VAChTimmunopositive somata and dendrites, as indicated by an asterisk (*).
bilized homogenates of rat brain were fractionated by SDS-PAGE and electroblotted overnight onto polyvinylidene fluoride membrane (Millipore, Bedford, MA). Blots were blocked with 5% dry milk in 50 mM Tris-buffered saline (TBS), pH 7.4, followed by overnight incubation with primary antibody (0.5 &ml) at 4°C. Membranes were rinsed and incubated for 1 hr with peroxidase-conjugated goat anti-rabbit IgG (BioRad) at room temperature. lmmunoreactivity was detected by enhanced chemiluminescence on film (Amersham, Buckinghamshire, UK). For preadsorption experiments, blots were incubated with primary antibody that had been preadsorbed with 100 kg of Ct-fusion protein conjugated to Affi-Gel 15 (BioRad) for 1 hr at room temperature.
Immunocytochemisfry.
Adult male Sprague-Dawley rats (n = 8) were given 300 IU of heparin i.p., deeply anesthetized with 4% chloral hydrate, and transcardially perfused with 0.9% saline with 0.005% sodium nitroprusside for 1 min, 3% paraformaldehyde (200 ml for 10 min), and 10% sucrose (200 ml for 10 min). Brains were removed and cryoprotected in 30% sucrose at 4°C. Fifty micron sections were cut on a freezing-sliding microtome and collected in 50 mM TBS, pH 7.2. Sections were preblocked in TBS with 4-S% normal goat serum (NGS), 0.1% Triton X-100, and avidin (10 @ml). Sections were then incubated in rabbit affinitv-ourified antibodv to VAChT 10.5 tie/ml). biotin (50 tipiml1, 2% NC&and 0.1% Triton k-100 for 2 d dt 4"C.-&ofinylated ioat &ti&bbit IgG secondary was used with 4% NGS and 0.1% Triton X-100 for 12 hr, and the avidin-biotin-complex method (ABC Elite; Vector, Burlingame, CA) was used to visualize immunoreactivity. Tissue was rinsed between all steps with TBS four times for 10 min each time. The peroxidase reaction was developed in 0.05% diaminobenzidine (DAB) and 0.01% H,O, until a dark brown reaction product was cvidcnt. Sections were rinsed several times in TBS, mounted on subbed slides, dchydratcd in alcohols, defatted in Histoclear (National Diagnostics, Atlanta, GA), and coverslipped for light microscopic analysis.
Control experiments were run in parallel to confirm specificity. Primary antibody was either omitted or was preadsorbed on the fusion protein conjugated to Affi-Gel 15 (BioRad) for 1 hr at room temperature. Monoclonal (Levey et al., 1983) and polyclonal (German et al., 1985) antibodies to ChAT were also used for comparison.
The immunocytochemistry procedure described above was modified as follows for electron microscopic localization of VAChT using immunoperoxidase and immunogold techniques. Glutaraldehyde (O.l-0.2%) was added to the fixative, and 40-50 pm tissue sections were cut on a Vibratome. Detergent was omitted from blocking and from antibody solutions for immunoperoxidase, which was visualized with DAB as described above. For immunogold, the blocking buffer contained 0.05% Triton X-100 and 5% NGS; for secondary, sections were incubated for 12 hr at 4°C in 1.4 nm gold-conjugated Fab fragments of goat anti-rabbit IgG at 1:50 (Nanoprobe, Stony Brook, NY). Silver enhancement of gold particles was performed using the HQ Silver kit from Nanoprobe. After it was immunostained, the tissue was postfixed with 1% osmium tetroxide and embedded in Eponate 12 (Ted Pella, Redding, CA), thin-sectioned at 60 nm on an ultramicrotome, and counterstained en block with 2% uranyl acetate (immunoperoxidase) or on grids with 5% uranyl acetate and Reynolds lead citrate [immunogold (Reynolds, 1963) ]. Tissue was analyzed on a Jeol JEM-100C transmission electron microscope (Joel, Peabody, MA).
For double-labeling experiments (n = 4), tissue was prepared by a modification of the procedure of Levcy et al. (l986) , whereby ChAT and VAChT were localized simultaneously. Sections were incubated in a mixture of affinity-purified antibodies to VAChT (0. I Kg/ml) and monoclonal antibody AB8 (Levey et al., 1983) to ChAT (1:200) for 48 hr. A combination of biotinylated goat anti-rabbit antibodies and goat antimouse antibodies preadsorbcd on rat brain powder were used as secondary antibodies with 12 hr incubations. Brown VACbT-like immunorcactivity was developed first using the avidin-biotin complex and visualized with DAB as above. Sections were rinsed thoroughly with TBS and sequentially incubated for 1 hr in mouse peroxidase anti-peroxidase (PAP), goat anti-mouse antibody, and PAP once again (Sternberger and Petrali, 1977) . Sections were rinsed three times in 0.01 M sodium phosphate buffer, pH 6.6, and all subsequent steps used this buffer only. Blue ChAT-like immunoreactivity was visualized with 0.01% benzidine dihydrochloride, 0.025% sodium nitroferricyanide, and 0.3% hydrogen peroxide on ice. Controls performed in parallel included the omission of one or both of the primary antibodies to ensure the specificity of each. Sections were rinsed immediately and mounted from phosphate buffer, dried overnight, and rinsed briefly in alcohol before coverslipping. RESULTS lmmunoblot analysis Affinity-purified antibodies against the C terminus were characterized by Western blotting against GST protein, GST/Ct-fusion protein, and membranes from HeLa cells transfected with pBIuescript or rat VAChT cDNA. The antibodies were strongly immunoreactive with the GST/Ct-fusion protein, which migrated at an apparent molecular weight (MW) of 35 kDa, although they did not react with GST, indicating that affinity-purified antibodies were specifically reactive with epitopes on the VAChT C-terminus portion of the fusion protein (Fig. L4) . When blotted against membrane proteins from HeLa cells transfected with VAChT cDNA, an intense band was detected at 50-55 kDa, with lighter bands at -70 and 120 kDa. A very faint band was also present at -35 kDa with longer exposures. No bands were present in the pBluescript vector-transfected cells. Preadsorption of the C-terminus antibody with GST/C terminus fusion protein eliminated all immunoreactive bands (Fig. L4 ). The regional distribution of VAChT immunoreactivity in the rat brain was investigated by Western blot analysis (Fig. 1B) . Broad single bands were present at -70 kDa in most regions. Striatum and amygdala exhibited the highest levels of immunoreactivity. Olfactory bulb, prefrontal cortex, sensorimotor cortex, septum/basal forebrain, hippocampus, thalamus, midbrain, and pons/meduIla exhibited intermediate levels of immunoreactivity. In contrast, very little immunoreactivity was present in cerebellum, a region with low levels of cholinergic innervation. Additionally, a faint band was present at -35 kDa, but only in those regions with the highest levels of the 70 kDa band. Because the 35 kDa band was also seen in transfected cells and it is smaller than the predicted MW of the core protein (56.5 kDa), it likely represents a degradation product. Preadsorption of the antibody abolished all immunoreactivity (data not shown). (Fig. 20) , mesopontine tegmental complex (Fig. 2F) , cranial nerve motor nuclei (Figs. 2G,H, 6C,D) , and ventral horn and intermediate zone of the spinal cord (see Fig. 6A,B) . All immunoreactivity was abolished with preadsorption of the antibody with GST/Ct-fusion protein (Fig. 3B) . The presence of intrinsic cortical neurons was ambiguous; rare, small, and lightly stained neurons were seen occasionally (Fig. 3C ), but they were much less apparent than the bipolar neurons visualized with polyclonal ChAT antibodies. Perikarya and proximal dendrites were filled with DAB reaction product at sites of VAChT immunoreactivity, whereas nuclear and glial labeling were absent. Within the basal forebrain and striatum, double-labeling experiments confirmed that ChAT and VAChT are coexpressed in these populations of neurons (Fig. 3F) .
VAChT immunocytochemistry in rat brain
VAChT-immunoreactive fibers and varicosities were present in many areas throughout the brain. In neocortex, immunoreactivity was concentrated generally in layers I, IV, and V, whereas layers II, III, and VI contained fewer puncta and fibers (Fig. 3C) . Olfactory cortex showed a particularly dense labeling compared with other cortical regions (Fig. 2&C) . In the hippocampal formation, area CA3 contained more puncta than CA1 did (Fig. 4A) . The highest density of puncta and fibers was present within and immediately surrounding the pyramidal cell layer, although staining was present throughout all layers (Fig. 4B) . The dentate gyrus also exhibited a laminar staining pattern, with the greatest density of puncta and fibers being present in the molecular layer just above the granule cell layer (Fig. 4B) .
In the olfactory bulb, puncta were relatively dense within the glomeruli and showed a graded pattern of staining within the various cell layers (Fig. 2,4) . The olfactory tubercle, islands of Calleja, and striatum contained densely stained neuropil and puncta ( Figs. 2B; 3A) . There was a marked mediolateral gradient of striatal staining with highest levels laterally in striatum. Puncta were present in all areas of the basal forebrain, admixed with the Gilmor et al. . VAChT i n Rat Brain and Cholinergic Synaptic Vesicles A E i :-;
..: ; .., I F , Figure 3 . Light microscopic localization of VAChT-immunoreactivity in forebrain. A, Coronal section stained with VAChT C-terminus antibodies (0.5 &ml). Stained cells are present in the medial septum (MS), vertical limb of the diagonal band (VDB), and striatum (CPU). Punctate staining is present throughout the cortex and is particularly dense in the primaty olfactory cortex (PO). Dense punctate labeling is also present in the olfactory tubercle (0, island of Calleja majoris (KjM), and striatum. Additional abbreviations: Par, parietal cortex; LS, lateral septum; ac, anterior commissure. B, Coronal brain section stained with VAChT C-terminal antibodies preadsorbed on 100 Fg of C-terminus fusion protein as described in Materials and Methods. C, VAChT-like punctate and fiber staining in the somatosensory cortex. Note the heavy labeling in layers I, IV, and V. Awows indicate possible VAChT-positive intrinsic cortical neurons. D, In striatum, dense neuropil staining is evident as are large cells with aspiny dendrites, typical of striatal cholinergic interneurons. E, Section of vertical limb of diagonal band is an enlargement of boxed area in A. Note the dense puncta in the neuropil surrounding immunoreactive perikarya. F, Example of a double-labeled cell in the diagonal band; VAChT-like immunoreactivity is present in the soma and proximal dendrites, and ChAT-immunoreactivity is granular and coexpressed in the soma. G, Enlargement of the boxed urea of the lateral septum in A. An unlabeled soma and proximal dendrites are outlined by a dense "basket-like" plexus of VAChT-like punctate immunoreactivity. Scale bars: A, B, 1000 ym; C-E, 50 pm; F, G, 10 pm. (Fig. 3E ). In the lateral septum, unlabeled cells were outlined by VAChT-immunoreactive puncta surrounding the ccl1 bodies and proximal dendrites (Fig. 3G) . Punctate reaction product was widespread in the thalamus, with particularly high levels in the anteroventral, mediodorsal, reticular, and intralaminar nuclei (Fig. 2C,D) . In the anteroventral nucleus, reaction product was most dense laterally and progressively less medially.
In the brainstcm, there was a widespread distribution of VAChT-immunoreactive puncta. The interpeduncular nucleus was one of the most heavily stained areas in the brain (Fig. 2E) . Varying levels were also found in the superior colliculus, pontine nuclei, red nucleus, cochlear nucleus, and dorsal raphe (Fig. 2F) . All somatic and visceral motor neurons in cranial nerve nuclei displayed VAChT immunoreactivity. Moreover, neurons and proximal dendrites in some of these nuclei, including the trigeminal, facial (see Fig. 60 ), and hypoglossal, as well as the anterior horn of the spinal cord (see Fig. 6A,B) , were covered in a plexus of particularly large, positively stained puncta. Subcellular localization of VAChT Electron microscopy was performed in the hippocampal formation, striatum, and motor nucleus of the facial nerve to evaluate the subcellular localization of VAChT. In addition to immunoperoxidase, which results in very sensitive but diffuse labeling, immunogold was used to determine more precisely the subcellular localization and topology of the VAChT C terminus. In the dentate gyrus, VAChT-immunopositivc terminals contained dense DAB reaction product, which filled the cytoplasm surrounding synaptic vesicles, and made symmetric contacts with unlabeled somata and dendrites (Fig. 4C,D,E) . Most silverintensified immunogold particles in CA3 were localized to synaptic vesicles in labeled terminals (Fig. 4F,G,H) ; some immunogold particles contacted the presynaptic density and terminal plasma membrane. The size of the immunogold particles made it difficult to determine on which side of the synaptic vesicle membrane the gold was deposited, but where possible, it appeared on the cytoplasmic side. In the striatum, VAChT-labeled somata conformed cytologically to large aspiny cholinergic interneurons (Fig. 5B ). DAB reaction product was associated mainly with the Golgi and endoplasmic reticulum, and nuclear labeling was not evident. Immunogold particles were present almost exclusively on the cytoplasmic face of the Golgi apparatus (Fig. 5E ). In the neuropil, immunogold-positive VAChT terminals were abundant and made symmetrical synapses with unlabeled dendrites and spines (Fig.  5C,D) . In the motor nucleus of the facial nerve, large somata filled with DAB reaction product, concentrated in the Golgi and endoplasmic reticulum, received contacts from VAChT-positive tcrminals (Fig. 6E) . These terminals contained dense DAB reaction product in the cytoplasm (Figs. 6&F) . Immunogold labcling yielded the same results but with more precise spatial localization; in terminals, the immunogold particles were associated selectively with synaptic vesicles (Fig. 6G,H) ; in perikarya, the immunogold particles were clearly localized on the cytoplasmic face of the endoplasmic reticulum (Fig. 6H) ; and in dendrites, the immunogold particles were associated primarily with smooth cndoplasmic reticulum (data not shown).
DISCUSSION
In the present study, highly specific antibodies to the rat VAChT were developed that enabled the first direct characterization of the encoded protein in rat brain. There were several major findings. First, the native protein has a MW of -70 kDa. Second, the protein is expressed selectively in all known chohnergic neurons; the use of double-labcling techniques confirms that ChAT and VAChT, which share a unique genetic arrangement, are colocalized at the protein level. Third, VAChT is localized to the synaptic vesicles of cholinergic axon terminals in the mammalian brain, demonstrating the morphological substrate of its suggested role as a vesicular transporter of ACh. Fourth, ultrastructural microscopic analysis using immunogold shows that VAChT is synthesized in the endoplasmic reticulum and Golgi apparatus with the C terminus in the cytoplasm; the same orientation is present in synaptic vesicles where discernible. This is consistent with topological models.
Antibody specificity The C terminus of the putative VAChT protein was chosen as a target epitope for antibody production because of its unique and divergent sequence from other vesicular transporter family members, as well as the predicted hydrophilicity and immunogenicity of this region. Several lines of evidence confirm the specificity of the antibodies.
First, the antibodies recognized the purified C-terminus fusion protein but not fusion proteins containing the N-terminus and loop regions (data not shown) or purified GST. Second, recognition of the full-length and mature forms of VAChT protein was demonstrated with Western blots of HeLa cells transfected with the rat VAChT cDNA and in rat brain. The dense 55-kDa band present in VAChT-transfected HeLa cells likely represents the core protein, predicted to have a MW of 56.5 kDa on the basis of the cDNA sequence (Bejanin et al., 1994; Erickson et al., 1994; Roghani et al., 1994) . The 70-kDa band present both in VAChT-transfected HeLa cells and in rat brain homogenates is possibly a mature, glycosylated form of the VAChT protein, because two N-linked glycosylation sites are present on the large intravesicular loop (Bejanin et al., 1994; Erickson et al., 1994; Roghani et al., 1994) . The protein is enriched in brain areas known to receive dense cholinergic innervation, such as striatum, hippocampus, and amygdala, with the lowest levels in cerebellum where there is little cholinergic input. Finally, the immunohistochemical data also strongly support the specificity of these polyclonal VAChT antibodies. The pattern of VAChT-immunoreactive neurons closely matches the distribution of VAChT mRNA, ChAT mRNA, and ChAT-immunoreactive perikarya, with the few mismatches only in areas where the existence of cholinergic cells is controversial (discussed below). The distribution of VAChT-immunoreactive fibers and their ultrastructural morphology also corresponds with that expected of cholinergic innervation. Thus, there is no doubt that the antibodies are highly specific for the VAChT protein.
Selective expression in cholinergic neurons VAChT immunorcactivity was concentrated in cell groups defined previously as cholincrgic by ChAT immunoreactivity and was also present in terminals and fibers of areas of known cholinergic innervation. VAChT-positive cells were present in all cholinergic nuclei of the basal forebrain (Chl-Ch4), including the medial septal nucleus, the vertical and horizontal limbs of the diagonal band of Broca, and the nucleus basalis of Meynert. The pedunculopontine nucleus (Ch5), laterodorsal tegmental nucleus (Ch6), medial habenula (Ch7), parabigeminal nucleus (Ch8), and cranial and spinal motor nuclei also contained labeled cells. The colocalization of ChAT and VAChT proteins in double-labeling experiments supports the idea of coregulation of these genes at their shared locus. Indeed, the VAChT gene lies within the first intron of the ChAT gene in all species studied to date. Moreover, the mRNAs and both encoded proteins, as shown here, are expressed uniquely in cholinergic neurons, providing more evidence that this genetic locus may be a regulon (Usdin et al., 1995) . VAChT mRNA species have been detected with the 5' exon R, originally found in ChAT mRNA, suggesting that some VAChT and ChAT transcripts may have their expression regulated by a common mechanism. Testing of this hypothesis and further study of the regulation of these genes will now be possible at the protein level using specific antibodies. The presence of cortical cholinergic neurons has been particularly controversial. ChAT-immunoreactive cortical bipolar neurons have been observed in rodents, but not in primates, with several different antibodies (Cozzari and Hartman, 1980; Eckenstein and Thoenen, 1982; Houser et al., 1983; Levey et al., 1984; German et al., 1985; Houser et al., 1985) ; however, in situ hybridization to ChAT mRNA has generally not detected positive intrinsic cortical neurons (Butcher et al., 1992 (Butcher et al., , 1993 Oh et al., 1992) with the only exception being in piriform cortex (Ibanez et al., 1991) . The cloning of the VAChT gene has provided the opportunity to look at this issue from a new angle. Unfortunately, the results are again ambiguous. Northern blot analysis and PCR experiments show weak signals for VAChT mRNA in cortex and hippocampus (Erickson et al., 1994; Roghani et al., 1994) . In situ hybridization studies to VAChT mRNA indicate the presence of VAChT-positive neurons in layers II and III of frontal, parietal, piriform, and occipital cortex but not in hippocampus (Schafer et al., 1994) . In the present immunohistochemical study, small neuronal soma are present in layers II and III of cortex, but they are lightly labeled and thus are difficult to identify definitely as positive (Fig. 3C) . VAChT protein may be present in very low levels in the soma of cortical neurons, perhaps being rapidly transported to terminals. More sensitive detection methods may be necessary Gilmor et al. . VAChT i n Rat Brain and Cholinerglc Synaptic Vesicles to visualize VAChT in somata, as was necessary for the visualization of ChAT (Levey et al., 1984) . It is also possible that the presence of VAChT mRNA is not reflected in actual levels of protein produced and used. Because five VAChT mRNAs have been identified to date (Cervini et al., 1995) , it is possible that the mRNA produced in cortical neurons does not lead to a mature, detectable VAChT protein.
Many regions of brain, including cerebral cortex, hippocampus, basal forebrain, thalamus, brainstem nuclei, cranial nerve motor nuclei, and spinal cord regions show varying degrees of cholinergic innervation as determined by VAChT immunohistochemistry. Cortical and hippocampal staining patterns match ChAT-immunoreactive fibers and terminals (Houser et al., 1983; Frotscher and Leranth, 1985; Houser et al., 1985; Matthews et al., 1987) , although the VAChT antibodies described here seem to result in more sensitive visualization of cholinergic terminals than most ChAT antibodies. For instance, in the basal forebrain, we found a surprisingly extensive degree of VAChT fibers and terminals. Cholinergic projections to the basal forebrain may arise from local collaterals of the magnocellular ChAT-immunoreactive neurons, or possibly from the mesopontine tegmental complex (Hallanger and Wainer, 1988) . The muscarinic effects of acetylcholine released from these terminals is believed to modulate septohippocampal activity and memory processing (Givens and Olton, 1990; Pang et al., 1993) . VAChT-positive terminals were also much more prominent than realized previously in the lateral septum. These cholinergic afferents presumably originate in the mesopontine tegmental complex and are believed to modulate REM sleep. Anatomical studies have demonstrated projections from the pedunculopontine nucleus to the lateral septum (Hallanger and Wainer, 1988) , and carbachol injections to the pedunculopontine tegmental nucleus immediately elicit hippocampal theta rhythms (Vertes et al., 1993) . The presence of baskets of VAChT-immunopositive puncta surrounding lateral septal cells underscores the importance of cholinergic modulation of these neurons. Additionally, we have confirmed the cholinergic nature of the previously defined C terminals (C for cisterns) on motor neurons in the brainstem and spinal cord (Connaughton et al., 1986; Nagy et al., 1993; Li et al., 1995) . Although these boutons are among the largest in the CNS, little is known of their origin or physiology.
Ultrastructural localization Immunogold electron microscopy demonstrated VAChT localization to synaptic vesicles in several regions with dense cholinergic innervation. The immunogold particles were almost exclusively associated with the small, clear synaptic vesicles in axon terminals that made symmetric contacts with dendrites and perikarya in the areas examined. This is the first direct evidence that the putative VAChT protein is indeed associated with synaptic vesicles in characteristic cholinergic terminals. Immunogold particles were also found in association with the presynaptic density and terminal plasma membrane, presumably through fusion of synaptic vesicles with the plasma membrane. Within labeled perikalya, the immunogold particles were associated with the Golgi apparatus and endoplasmic reticulum, as expected for a membrane-bound protein.
Topology
The topological models of the VAChT protein, like the other vesicular transporter family members, have been based primarily on two factors. First, hydropathy analysis has been used to predict the 12-transmembrane structure. Second, the location of phosphorylation and glycosylation consensus sequences have suggested that both termini are in the cytoplasm and that the predicted loop between transmembrane domains I and II resides within the vesicular lumen; however, there has been no direct support of these models until now. Both immunoperoxidase and immunogold electron microscopy support the C terminus being located in the cytoplasm. DAB reaction product was found in the cytoplasm, not intravesicularly. Immunogold particles were localized on the cytoplasmic face of the endoplasmic reticulum and Golgi apparatus and on synaptic vesicles where discernible. Additional topological assessment requires the development of antibodies to epitopes on the N terminus or intravesicular loop and biochemical analysis.
In conclusion, antifusion protein antibodies were developed and used to demonstrate that the VAChT protein is an excellent and highly specific marker of cholinergic neurons, fibers, and terminals. Immunoblotting and immunohistochemistry localized VAChT in brain regions known or suspected to contain cholinergic cells and terminals. Electron microscopy supports VAChT as an integral membrane synaptic vesicle protein with the C terminus in the cytoplasm. These antibodies will be useful for studies of the regulation of the shared ChAT and VAChT genetic locus, not only in normal tissue but also in pathological conditions such as Alzheimer's disease.
